分阶段立体定向序贯推量在选定的胶质母细胞瘤患者中的应用：单机构分析。

Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis.

机构信息

Radiation Oncology Section, University of Perugia, Perugia, Italy.

Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy.

出版信息

Anticancer Res. 2020 Jun;40(6):3387-3393. doi: 10.21873/anticanres.14322.

DOI:10.21873/anticanres.14322

PMID:32487635

Abstract

AIM

To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group.

PATIENTS AND METHODS

Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis.

RESULTS

The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS.

CONCLUSION

In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival.

摘要

目的

回顾性评估 15 例经化疗-放疗（CHT-RT）后序贯分割立体定向放疗（FSRT）推量治疗的胶质母细胞瘤患者的毒性和生存情况，并将其生存结果与对照组进行比较。

患者和方法

采用 CTCAE 3.0 量表评估毒性。采用 Kaplan-Meier 法设计生存曲线，对数秩检验进行双变量分析，Cox 比例风险回归模型进行多变量分析。

结果

中位随访时间为 16 个月（范围=5-60）。发生 1 例头痛和 1 例放射性坏死（RN）。在推量组中，中位总生存期（OS）为 25 个月，在无推量组中为 14 个月（p=0.004）。在推量组中，中位无进展生存期（PFS）为 15 个月，在无推量组中为 8 个月（p=0.046）。多变量分析显示，FSRT 推量与 OS 和 PFS 显著相关。